Cough syrups require doctor’s prescription for purchase, to not fall under OTC, says Health Ministry

Health Ministry Updates Cough Syrup Regulations: Prescription Required

Theindiapostdaily.com – Cough syrups require doctor’s prescription under the newly amended Drugs Rules, 2026, according to the Indian Health Ministry. This decision marks a significant shift in how these medications are classified and sold, moving them from over-the-counter (OTC) to prescription-only status. The change comes in response to rising concerns about the safety of cough syrups, particularly following incidents of contamination that resulted in child deaths in multiple states. By requiring a doctor’s prescription for purchase, the ministry aims to tighten oversight and reduce the risk of misuse or administration of substandard products.

Background and Regulatory Changes

The Health Ministry’s update to the Drugs (Fifth Amendment) Rules, 2026, removes cough syrups from Schedule K, which previously listed OTC exempt medicines. This adjustment was made under the authority of the Drugs and Cosmetics Act, 1940, and takes effect upon publication in the Official Gazette. The key modification involves deleting “Syrups” from item seven of the “Class of Drugs” section, effectively reclassifying these products as prescription medicines. This ensures that only licensed pharmacists or healthcare professionals can distribute cough syrups, adding an extra layer of control over their sale.

The rationale for this change is rooted in the need for stricter quality checks. The Ministry highlighted that cough syrups, which are often consumed by children, pose unique risks when improperly manufactured or stored. By mandating a doctor’s prescription, the regulation ensures that patients receive guidance on correct usage, dosage, and potential side effects. This shift also aligns with recommendations from the National Human Rights Commission (NHRC) and the World Health Organisation (WHO), which have both raised alarms about the safety of these products.

Contamination Incidents and Public Health Concerns

Earlier this year, the NHRC launched an investigation after reports of contaminated cough syrups were linked to several child deaths in states like Madhya Pradesh, Rajasthan, and Uttar Pradesh. The Commission’s report emphasized that these tragedies underscored critical gaps in drug regulation and the importance of enforcing stringent safety standards. The NHRC urged state governments to halt the sale of suspected syrups and to conduct immediate tests to identify contamination sources.

“The incidents have exposed the vulnerabilities in our drug supply chains, and enhanced surveillance of the informal market is essential,” stated the WHO in a report cited by PTI.

The World Health Organisation (WHO) had previously issued a medical alert in October 2023, identifying three Indian-made cough syrups—Coldrif, Respifresh TR, and ReLife—as substandard due to the presence of Diethylene Glycol (DEG), a toxic substance linked to kidney failure. The WHO’s warning prompted the Health Ministry to expedite regulatory changes, ensuring that these products are no longer available without professional oversight.

These contamination cases highlight the necessity of the new rules. While OTC medicines are accessible to the public, they are subject to less rigorous scrutiny. By requiring a doctor’s prescription, the ministry ensures that syrups are only dispensed after a thorough evaluation of the patient’s condition. This measure is expected to prevent the widespread distribution of counterfeit or adulterated products, particularly those that have been implicated in severe health complications.

Implementation and Consumer Impact

With the new rules in place, consumers must now obtain a prescription from a qualified medical practitioner to purchase cough syrups. This process involves a consultation where the doctor assesses the patient’s symptoms, medical history, and appropriate dosage. The change also affects pharmacies, which must verify prescriptions before dispensing the medication. While this may add a minor inconvenience for users, it is intended to safeguard public health and reduce the likelihood of adverse effects.

The Health Ministry’s decision is part of a broader effort to modernize drug regulations and align them with global safety standards. According to the amendment, the updated rules will apply to all syrup-based formulations, ensuring consistency in their classification. This approach not only addresses immediate safety concerns but also sets a precedent for reclassifying other OTC medicines if similar risks are identified. The emphasis on prescription requirements reflects a growing commitment to patient-centric healthcare practices.

Industry stakeholders have welcomed the change, acknowledging its role in improving medication safety. However, some experts argue that the rule could increase the burden on healthcare providers and potentially raise the cost of cough syrups for consumers. Despite these concerns, the Health Ministry maintains that the benefits of stricter regulation outweigh the challenges, especially in light of the recent tragedies linked to contaminated products.

Cough syrups require doctor’s prescription to ensure that they are used responsibly and only when necessary. This update also reinforces the importance of adherence to quality standards in pharmaceutical manufacturing. As the new rules take effect, the ministry will monitor their implementation closely to address any emerging issues and provide further guidance to healthcare professionals and consumers.